{"id":"W4417466987","doi":"10.1159/000549955","title":"Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis","year":2025,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Durvalumab; Tremelimumab; Hepatocellular carcinoma; Phases of clinical research; Ramucirumab; Chemoradiotherapy; Carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002030261,0.0003273427,0.000627781,0.00008266926,0.000265777,0.00004446017,0.00009205862,0.00009028929,0.00004813815],"category_scores_gemma":[0.000058241,0.0001969238,0.00009479438,0.0002785103,0.00012839,0.00008447171,0.00006012235,0.00009412164,0.000001460187],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001605568,"about_ca_system_score_gemma":0.0002473677,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03032082,"about_ca_topic_score_gemma":0.004225269,"domain_scores_codex":[0.9981744,0.0001038022,0.0004437734,0.0006124702,0.0002732048,0.0003924069],"domain_scores_gemma":[0.9987043,0.0004307927,0.0001504298,0.0003841407,0.0001638105,0.0001666012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01994115,0.002370124,0.9506425,0.0001141426,0.001475258,0.0001349787,0.00816974,0.000002494801,0.0003170493,0.00001363954,0.0001281238,0.01669078],"study_design_scores_gemma":[0.1488496,0.03310804,0.7462116,0.000903033,0.01030821,0.0000121085,0.003221436,0.02077254,0.03094919,0.00006416881,0.005056921,0.0005432209],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852231,0.007714768,0.00002417537,0.001436212,0.0000535673,0.00481498,0.0005688763,0.00003245966,0.0001318401],"genre_scores_gemma":[0.9963387,0.0009833388,0.0001294169,0.0001145513,0.00008425508,0.001452063,0.00009002828,0.00003200841,0.0007756401],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2044309,"threshold_uncertainty_score":0.9761364,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09119294205123218,"score_gpt":0.3126555805677392,"score_spread":0.221462638516507,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}